GlassScriptPhysician profile
Andrew John Cooke
NPI 1477852689
$16,779.66
in general payments reported to CMS, 2019-2025
41 companies · $4,615 in 2025
The $4,615 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $894 · 2021: $1,798 · 2022: $3,646 · 2023: $2,269 · 2024: $3,041 · 2025: $4,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,746 · Education: $139 · Consulting Fee: $39.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,746.22 |
| Education | $139.26 |
| Consulting Fee | $39.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,666.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,272.47 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $1,290.11 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $1,232.25 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pharming Healthcare, INC. | $1,210.25 | 2021-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $1,204.32 | 2019-2025 | Dupixent |
| Pfizer INC. | $899.36 | 2019-2025 | |
| Csl Behring | $754.90 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Octapharma USA, INC. | $646.70 | 2019-2022 | |
| Amgen INC. | $582.37 | 2021-2025 | Actimmune, Tezspire, Otezla |
| Optinose US, INC. | $450.16 | 2020-2025 | |
| Grifols USA, LLC | $403.76 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Alk-Abello, INC | $339.64 | 2020-2025 | Ragwitek, Grastek, Odactra |
| Biocryst US Sales Co., LLC | $315.53 | 2022-2025 | Orladeyo |
| Blueprint Medicines Corporation | $256.54 | 2023-2025 | Ayvakit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.